Skip to main content
Download PDF

The first nationwide multicenter study of Acinetobacter baumannii recovered in Serbia: emergence of OXA-72, OXA-23 and NDM-1-producing isolates

Antimicrobial Resistance & Infection Control volume 9, Article number: 101 (2020) Cite this article

Abstract

Background

The worldwide emergence and clonal spread of carbapenem-resistant Acinetobacter baumannii (CRAB) is of great concern. The aim of this nationwide study was to investigate the prevalence of CRAB isolates in Serbia and to characterize underlying resistance mechanisms and their genetic relatedness.

Methods

Non-redundant clinical samples obtained from hospitalized patients throughout Serbia were included in the prospective, observational, multicenter study conducted from January to June 2018. Samples were initially screened for the presence of Acinetobacter baumannii-calcoaceticus (Acb) complex using conventional bacteriological techniques. Acb complexes recovered from clinical samples obtained from inpatients with confirmed bacterial infections were further evaluated for the presence of A. baumannii. Identification to the species level was done by the detection of the blaOXA-51 gene and rpoB gene sequence analysis. Susceptibility testing was done by disk diffusion and broth microdilution method. CRAB isolates were tested for the presence of acquired carbapenemases (blaOXA-24-like, blaOXA-23-like,blaOXA-58-like, blaOXA-143-like, blaIMP, blaVIM, blaGIM, blaSPM, blaSIM, blaNDM) by PCR. Clonal relatedness was assessed by pulsed-field gel electrophoresis (PFGE) and multilocus sequence typing (MLST).

Results

Acb complex was isolated in 280 out of 2401 clinical samples (11.6%). Overall, A. baumannii was identified in 237 out of 280 Acb complex (84.6%). CRAB prevalence was found to be 93.7% (237/222). The MIC50/MIC90 for imipenem and meropenem were 8/> 32 μg/mL and 16/> 32 μg/mL, respectively. Although susceptibility was high for colistin (95.7%; n = 227) and tigecycline (75.1%; n = 178), ten isolates (4.3%) were classified as pandrug-resistant. The following carbapenemases-encoding genes were found: 98 (44.2%) blaOXA-24-like, 76 (34.5%) blaOXA-23-like, and 7 (3.2%) blaNDM-1. PFGE analysis revealed six different clusters. MLST analysis identified three STs: ST2 (n = 13), ST492 (n = 14), and ST636 (n = 10). Obtained results evaluated that circulating CRAB clones in Serbia were as follows: blaOXA66/blaOXA23/ST2 (32.4%), blaOXA66/blaOXA23/blaOXA72/ST2 (2.7%), blaOXA66/blaOXA72/ST492 (37.8%), and blaOXA66/blaOXA72/ST636 (27.1%).

Conclusion

This study revealed extremely high proportions of carbapenem resistance among A. baumannii clinical isolates due to the emergence of blaOXA-72, blaOXA-23, and blaNDM-1 genes among CRAB isolates in Serbia and their clonal propagation.

Background

In the recent years Acinetobacter baumannii has rapidly emerged as significant opportunistic pathogen and major cause of morbidity and mortality in the healthcare settings. The abilities of the organism to long-term survive in the hospital environment, rapidly develop antibiotic resistance and spread clonally potentiate the persistence and transmission of the species in healthcare settings. Consequently, A. baumannii is able to cause a spectrum of severe nosocomial infections such as ventilator-associated pneumonia, wound infections, bloodstream infections, meningitis, and urinary tract infections. The high risk populations are debilitating patients, those admitted to the intensive care units (ICUs), attached to indwelling foreign devices or mechanically ventilated [1, 2].

A. baumannii has a numerous inherent and acquired resistance mechanisms which dramatically reduce the existing therapeutic options [3]. Consequently, A. baumannii is one of the ESKAPE organisms (Enterococcus faecium, Staphylococcus aureus, Klebsiella pneumoniae, Acinetobacter baumannii, Pseudomonas aeruginosa, and Enterobacter species), a group of clinically important pathogens that have the potential for substantial antimicrobial resistance [4]. Carbapenems used to be the mainstay for the treatment of nosocomial infections caused by A. baumannii [3]. However, the resistance to carbapenems has rapidly emerged and resulted in the worldwide dissemination of carbapenem-resistant A. baumannii (CRAB) strains, which usually exhibits a multidrug-resistant (MDR) phenotype, raising serious concerns about available treatment options [5, 6]. In addition, CRAB is one of the critical-priority pathogens on the World Health Organization priority list of antibiotic-resistant bacteria for effective drug development [7]. Moreover, in critically ill patients in the ICUs infected with MDR A. baumannii, there is a substantial rise in patient mortality rates [8]. According to the most recent data from Centers for Disease Control and Prevention CRAB is listed as urgent threat in the United States with 8.500 cases and 700 deaths in hospital settings in 2017 [9].

Carbapenem resistance in Acinetobacter is mostly associated with the production of carbapenem-hydrolyzing enzymes, Ambler class D β-lactamases or oxacillinases (OXAs) [10]. Although the OXAs weakly hydrolyze carbapenems, they can confer higher resistance when blaOXA genes are overexpressed using a strong promoter with mobile insertion elements such as ISAba1 [11]. Less frequent, but much powerful carbapenem-hydrolyzing enzymes in A. baumannii belong to class B β-lactamases or metallo-β-lactamases (MBLs) [10, 12].

There are numerous reports about the dissemination of CRAB strains, carriers of the OXA and MBL genes, from different geographical areas around the world [5, 12, 13]. Molecular typing of the CRAB strains from various European hospitals has shown the emergence of three successful clones originally named European clones I to III, which were renamed as international clones (ICs) I to III, after been identified worldwide [14]. In Serbia, there is no data on molecular epidemiology of CRAB in adult patients. So far, there is just one study, reporting the distribution of carbapenemase encoding genes among clinical isolates of A. baumannii from a single pediatric hospital [15]. However, there are several reports on OXA and MBL-positive CRAB strains, recovered from patients migrating from Serbia to Western Europe [16, 17].

Therefore, the aims of this nationwide multicenter study were: i) to evaluate the prevalence and antimicrobial resistance patterns of A. baumannii circulating in Serbia, ii) to determine the prevalence of OXAs and MBLs among CRAB isolates, and iii) to assess their genetic relatedness and identify disseminated CRAB clones.

Methods

Study design and setting

The study was designed as a prospective, observational multicenter study. Serbia is Southeastern European country with roughly seven million inhabitants. It could be arbitrarily divided into three regions: Belgrade (the capital, two million), South Serbia (three million) and Vojvodina (two million). In the present study, regional microbiological laboratories from seven cities across Serbia evaluated 2401 randomly selected clinical specimens recovered from inpatients with confirmed bacterial infections admitted at nine hospitals throughout Serbia during the period January–June 2018. Microbiological laboratories from each region of the country evaluated the following number of hospital specimens: Vojvodina, n = 800 (General hospital Subotica, General hospital Pancevo, General hospital Sombor and Institute for pulmonary diseases of Vojvodina), Belgrade, n = 801 (University hospital medical center Bezanijska kosa, University hospital center dr Dragisa Misovic, Institute for cardiovascular diseases Dedinje), and Southern Serbia n = 800 (Clinical center Kragujevac, Clinical center Nis). All isolated Acinetobacter calcoaceticus–baumannii (Acb) complexes were sent to the coordinating laboratory at the Institute of Microbiology and Immunology of Medical Faculty University in Belgrade for further investigation. The inclusion criteria was the isolation of the Acb complex from non-redundant clinical samples (one per infected patient) obtained during the routine laboratory work. Infection was diagnosed using corresponding clinical and laboratory criteria. The exclusion criteria were detection of the non-Acb complex microbial agents as a possible source of infection and/or isolation of Acb complex without any clinical manifestations related to infection or without positive laboratory inflammatory markers. We addressed the potential bias of misdiagnosis of infectious disease by having the diagnostic criteria validated by an independent physician. This physician was blinded in terms of medical records.

Bacterial isolation and identification

Bacterial isolation and identification of Acb complex was done during the routine work in regional clinical laboratories by VITEK®2 system (bioMérieux, Marcy-l’Étoile, France) and conventional bacteriological techniques, such as colony appearance on sheep blood agar and MacConkey agar, Gram staining, motility test and biochemical characteristics.

All isolated Acb complexes together with the following data: type of specimen, ward of admission, patients’ age, gender, clinical diagnosis, underlying conditions and other risk factors were sent to the coordinating laboratory for further investigation. All patients were de-identified in regional clinical laboratories and re-coded, before the bacterial strains were sent to the coordinating laboratory. The study was approved by the ethical committee of the Medical Faculty, University of Belgrade (1550/II-4).

Species identification was done in the coordinating laboratory. The DNA from an overnight culture on Columbia blood agar was extracted using a QIAamp DNA Mini Kit (QIAGEN GmbH, Hilden, Germany) according to the manufacturer’s instructions. All isolates of Acb complex were initially screened for the presence of A. baumannii by PCR detection of the intrinsic blaOXA-51 gene, as previously reported [18]. The primers are shown in Table 1. The species identification was then confirmed by rpoB gene sequence analysis, as previously described [23]. All identified A. baumannii strains were stored at − 80 °C until further analysis.

Table 1 Primers used in this study
Full size table

Antimicrobial susceptibility testing

Antimicrobial susceptibility of A. baumannii to ampicillin-sulbactam (AMS), piperacillin-tazobactam (TZP), ceftazidime (CAZ), cefepime (FEP), meropenem (MER), imipenem (IMP), gentamicin (GEN), amikacin (AK), tobramycin (TOB), tetracycline (TET), ciprofloxacin (CIP), levofloxacin (LEV), and trimethoprim-sulfamethoxazole (TSX) was determined by disk-diffusion assay (Bio-Rad, UK), following the Clinical and Laboratory Standards Institute (CLSI) guidelines [24]. Minimum inhibitory concentrations (MICs) for colistin (COL), IMP and MER were evaluated by ComASP Colistin (Liofilchem, Italy) and Gradient strip test (Liofilchem, Italy), respectively. MICs for tigecycline (TYG) were assessed by broth microdilution method with Mueller-Hinton broth (Bio-Rad, UK), following the CLSI guidelines [24]. Susceptibility categories were interpreted according to the CLSI criteria [24] for all antibiotics except for TYG which was interpreted according to the European Committee on Antimicrobial Susceptibility Testing (EUCAST) breakpoints for Enterobacterales (S ≤ 1 μg/mL; R > 2 μg/mL), since the breakpoints for TYG susceptibility against A. baumannii have not been determined yet [25]. Escherichia coli ATCC 25922 and Pseudomonas aeruginosa ATCC 27853 were used as quality control strains. The isolates of A. baumannii were classified as follows: multidrug-resistant (MDR) [resistant to at least one agent in three or more antimicrobial categories], extensively drug-resistant (XDR) [resistant to at least one agent in all, but two or fewer antimicrobial categories] and pandrug-resistant (PDR) [resistant to all agents in all antimicrobial categories tested] [26]. Additionally, IMP resistant A. baumannii isolates were selected for the phenotypic detection of MBL production by imipenem-EDTA combined disk test [27].

Detection of carbapenemase encoding genes and ISAba1 element

All CRAB isolates were screened for the presence of blaOXA-23-like, blaOXA-24-like, blaOXA-58-like, blaOXA-143-like, blaIMP, blaVIM, blaGIM, blaSPM, blaSIM and blaNDM with primers published elsewhere (Table 1) [19,20,21]. Multiplex PCRs were performed with separate groups of 4–6 primers and following the same thermal cycling conditions: initial denaturation at 94 °C for 10 min and 36 cycles of amplification consisting of 30 s at 94 °C, 40 s at 52 °C, and 50 s at 72 °C, with 5 min at 72 °C for the final extension. Deionized distilled water was used as the negative control and isolates whose sequences were previously confirmed were used as the positive control. ISAba1 was detected performing uniplex PCR, as previously reported [22]. The primers are shown in Table 1. Randomly selected OXA and all MBL amplicons of CRAB isolates were purified using the QIAquick PCR Purification Kit (QIAGEN GmbH, Hilden, Germany) following manufacturer’s instructions and sequenced using conventional Sanger sequencing method. The obtained sequences were searched for homology with sequenced genes in the GenBank database using the National Center for Biotechnology Information’s BLAST search program 2.7.0 for nucleotides (http://www.ncbi.nlm.nih.gov). All gene sequences (manually checked) and reference strain sequences from GenBank database were aligned using CLUSTAL W implemented in BioEdit ver. 7.1.3 software.

Molecular typing

Pulsed-field gel electrophoresis (PFGE) analysis

PFGE included 60 CRAB isolates randomly selected from all participating hospitals, with respect to the specimen types and gene content. PFGE was performed with a 2015 Pulsafor unit (LKB Instruments, Broma, Sweden), as previously described [28]. DNA restriction was done with ApaI enzyme (Thermo Scientific, Lithuania). The Lambda Ladder 48.5–727.5 kb PFG Marker (New England Biolabs, US) was used as DNA size marker. The stained gels were scanned using the Diversity Database software image-capturing system (Bio-Rad Laboratories Ltd., UK). The Dice coefficient was used to calculate similarities of the banding patterns with a tolerance of 1.5%, and the unweighted-pair group method using average linkages (UPGMA) was used for cluster analysis with BioNumerics software, version 4.0 (Applied Maths, St-Martens-Latem, Belgium). The isolates with more than 80% similarity in their DNA patterns were defined as genetically related and part of the same cluster.

Multilocus sequence typing (MLST) analysis

At least 50% of the CRAB isolates from each PFGE cluster and at least one isolate from each participating hospital, endowed with different blaOXA gene content were selected for MLST analysis. Overall, 37 isolates were typed by MLST under the Pasteur MLST scheme which involved PCR amplification, purification and sequencing of seven housekeeping genes (fusA, gltA, pyrG, recA, cpn60, rpoB, and rplB), as indicated previously [29]. Sequence types (STs) were assigned using the same scheme from the MLST website (http://pubmlst.org/abaumannii/).

Statistical analysis

Statistical analysis was done using SPSS version 14.0 (Chicago, Illinois USA). Statistical significance was assessed using the χ2 test or Fisher’s exact test, as appropriate. A P ≤ 0.05 value was considered to be significant.

Results

Bacterial isolates

During the study period, 2401 clinical samples were screened for inclusion (Fig. 1). A total of 280 (11.6%) isolates of Acb complex recovered from clinical samples fulfilled inclusion criteria. A. baumannii was identified in 237 out of 280 isolates of Acb complex (84.6%). Overall, the prevalence of the infections caused by A. baumannii were as follows: sepsis (n = 28/351; 7.9%), lower respiratory tract infections (n = 89/319; 27.9%), skin and soft tissue infections (n = 87/511; 17%), meningitis (n = 1/34; 2.9%), central venous catheter-related infections (n = 14/94; 14.9%), and urinary tract infections (n = 18/1092; 1.6%). Most of the A. baumannii isolates were obtained from the ICU (39.6%). Bacterial isolates were predominantly recovered from lower respiratory tract specimens (37.6%), wound exudates (36.7%) and blood samples (11.8%). Majority of the patients were elderly men (median age 66; within the range 14–87). Diabetes mellitus (23.2%) and surgical procedures (46.8%) were the most commonly reported underlying conditions. Detail information concerning specimen types, patient characteristics, underlying conditions, and risk factors are listed in Table 2.

Fig. 1
figure1

Flowchart of the process of Acb complex inclusion and strain selection for further molecular evaluation. Inclusion criteria was isolation of the Acb complex from non-redundant clinical samples (one per infected patient) obtained during the routine laboratory work. Acb complex - Acinetobacter calcoaceticus–baumannii complex; A. baumannii - Acinetobacter baumannii; BMD - Broth microdilution; CRAB - Carbapenem-resistant A. baumannii; DD - Disk diffusion; MLST - Multilocus sequence typing; PFGE - Pulsed-field gel electrophoresis

Full size image
Table 2 Demographic and clinical characteristics of Acinetobacter baumannii-infected study patients
Full size table

Antimicrobial resistance

The antibiotic resistance patterns of 237 A. baumannii isolates are shown in Table 3. CRAB prevalence was found to be 93.7%. Three isolates were resistant to MER and sensitive to IMI, while 219 (92.4%) were resistant to both IMP and MER. Fifteen isolates (6.3%) were fully susceptible to carbapenems. The MICs of the tested carbapenems were 2–256 μg/mL. The MIC50/MIC90 for IMP and MER were 8/> 32 μg/mL and 16/> 32 μg/mL, respectively. Carbapenem resistance rate was higher in non-invasive (94.9%) than in invasive (92.1%) A. baumannii isolates. However, statistical significance was not observed (P > 0.05). Moderate resistance rates were observed for AMS (59.1%) and TOB (68.8%). The drugs for which susceptibility was highest were the last-resort drugs, COL (95.7%) and TYG (75.1%). Thus, the MICs for COL ranged from < 0.25 to 4 μg/mL with MIC50/MIC90 values < 0.25/1 μg/mL, while the MICs for TYG ranged from 0.125–16 μg/mL with MIC50/MIC90 values 2/8 μg/mL. Resistance rates for all tested antibiotics were higher in ICU compared to other wards (Fig. 2), with the statistical significance for AMS, IMP and MER (P < 0.05). Although geographical differences of the proportion of CRAB isolates were detected (Vojvodina-91.5%; Belgrade-87.5%; Southern Serbia-96.3%), statistical significance was not observed (P > 0.05). Overall, CRAB isolates exhibited higher resistance rates to all antimicrobials as compared to carbapenems-susceptible A. baumannii (Table 3), with the exception of TYG and COL. Two hundred and three (85.6%) isolates were considered MDR. Ninety-five isolates (40%) displayed an XDR phenotype. Furthermore, ten isolates (4.3%) were classified as PDR. MDR, XDR and PDR were more prevalent in the ICU than in other hospital units. The phenotypic method revealed MBL production in 5 (2.23%) out of 222 CRAB strains.

Table 3 Antimicrobial resistance of the A. baumannii isolates resistant and susceptible to carbapenems
Full size table
Fig. 2
figure2

Antimicrobial resistance of A. baumannii in different hospital wards. AMS – ampicillin-sulbactam; TZP - piperacillin-tazobactam; CAZ - ceftazidime; FEP - cefepime; MER - meropenem; IMP - imipenem; GEN - gentamicin; AK - amikacin; TOB - tobramycin; TET - tetracycline; CIP - ciprofloxacin; LEV - levofloxacin; TSX - trimethoprim-sulfamethoxazole; COL - colistin; TYG - tigecycline.*P < 0.05

Full size image

Detection of carbapenemase encoding genes and ISAba1 element in A. baumannii

A total of 237 A. baumannii isolates harbored the naturally occurring blaOXA-51-like gene. Out of 222 CRAB isolates, 98 isolates (44.2%) carried blaOXA-24-like and 76 isolates (34.5%) carried blaOXA-23-like genes. Two isolates had both blaOXA-23 and blaOXA-24 genes, simultaneously. However, blaOXA-58-like and blaOXA-143-like genes were not detected in the tested population. Overall, ISAba1 was present in 161 (71.8%) CRAB strains. The co-existence of ISAba1/blaOXA-51-like, ISAba1/blaOXA-24-like, ISAba1/blaOXA-23-like and blaOXA-51/blaOXA-23/blaOXA-24 genes was detected in 16.5, 28.1, 26.7, and 0.5% of CRAB strains, respectively. The blaNDM was the only MBL gene detected in the study (n = 7). Sequencing of the blaNDM genes in all 7 isolates revealed the presence of the blaNDM-1 variant. Furthermore, all blaNDM-1 positive A. baumannii were blaOXA-24 positive isolates. None of the isolates carried blaIMP, blaVIM, blaGIM, blaSPM and blaSIM genes. There were no substantial differences between the hospitals and regions regarding the proportion of isolates carrying different acquired OXA genes. However, blaNDM-1 positive isolates were detected only in two cities: Belgrade (the capital) and Nis (the city in Southern Serbia).

Molecular typing

The results of PFGE and MLST analysis of the tested CRABs, along with the information on the hospital locations, intrinsic and acquired OXA gene content are summarized in Fig. 3.

Fig. 3
figure3

Dendrogram of the pulsed-field gel electrophoresis patterns of the A. baumannii strains isolated from nine regional hospitals in Serbia showing clusters (A-F); carriage of intrinsic (iOXA) and acquired blaOXA variants (aOXA); sequence type (ST) and corresponding international clone (IC), and hospital location

Full size image

The clonal relatedness of 60 CRAB isolates obtained from all participating hospitals was initially studied by PFGE. The similarity of the tested CRAB isolates ranged from 70 to 99%. Overall, PFGE analysis revealed six different clusters (A-F) and three singletons (Fig. 3). Largest clusters B, C and D which contained 5 (8.3%), 33 (55%), and 12 (20%) isolates, respectively, were comprised of CRAB isolates from Vojvodina, Belgrade and Southern Serbia. Isolates in cluster B and C were associated with the carriage of both blaOXA-24-like and blaOXA-23-like carbapenemases. Isolates of the remaining four clusters [cluster A (n = 3, 5%), cluster D (n = 12, 20%), cluster E (n = 2, 3.3%), and cluster F (n = 2, 3.3%)] were more homogenous and carried only blaOXA-24-like genes. Based on the PFGE clustering, OXA genes content, and hospital origin, out of 60 CRAB isolates analyzed by PFGE, 37 were selected for further characterization by MLST and OXA gene sequencing.

MLST assigned the analyzed CRAB isolates to 3 STs: ST2 (n = 13), ST492 (n = 14), and ST636 (n = 10). ST2 and ST492 (a single locus variant of ST2) belonged to ICII. ST 636 (a triple locus variant of ST2) was a singleton, not categorized in any IC. The blaOXA-23 positive isolates, were all assigned to ST2, blaOXA-24 positive belonged to ST492 and ST636, while blaNDM-1 positive strains were identified as ST2 or ST492. All three STs were evenly distributed in Vojvodina, Belgrade and Southern Serbia. Sequencing of the acquired class D OXA genes in all selected isolates revealed the presence of the blaOXA-72 variant in all blaOXA-24-like positive isolates and blaOXA-23 allele in all blaOXA-23-like positive isolates. Sequencing of the intrinsic class D OXA gene identified blaOXA-66 gene in all 37 isolates tested (Fig. 3). Therefore, detected clones of CRAB isolates circulating in Serbia were as follows: blaOXA66/blaOXA23/ST2 (32.4%), blaOXA66/blaOXA23/blaOXA72/ST2 (2.7%), blaOXA66/blaOXA72/ST492 (37.8%), and blaOXA66/blaOXA72/ST636(27.1%).

Discussion

A. baumannii poses a significant challenge to clinicians due to the increased incidence of hospital-acquired infections and its emergence of drug-resistance. This is the first Serbian nationwide multicenter study, providing data about the carbapenem resistance and clonality assessments of A. baumannii recovered from different hospitals throughout the country.

As expected, the vast majority of the Acb complexes tested in the present study was identified as A. baumannii (84.6%). Indeed, A. baumannii is the species of Acb complex most frequently involved in nosocomial outbreaks or sporadic infections [13]. Results of this study indicated that the prevalence of bloodstream infections caused by A. baumannii in Serbia (7.9%) is comparable to those found in some African and Asian countries (Morocco: 9.2%; India: 7.5%) [30, 31]. More than one-third of the tested A. baumannii recovered from clinical specimens were of respiratory origin (37.6%). The respiratory tract has already been confirmed to be the most common isolation site of A. baumannii [13]. Furthermore, nearly 50% of the isolated A. baumannii in Mexican tertiary care hospital were of respiratory origin while a 42.6% were found in Chinese university hospital, within a 3-year study period [32, 33]. Within our study, the second most common isolation site of A. baumannii was wound tissue (36.7%). Slightly lower isolation rates were recorded in China (burn wards: 25.2%; general surgery wards: 32.2%) [33] and in Mexico (23.2%) [32]. It is necessary to emphasize that the high rates of our A. baumannii isolated from wound exudates, point out the necessity of the strict following infection control measures, especially those focusing on the minimizing the transmission rate. In addition, various risk factors noticed in the present study, have already been significantly associated with infections caused by A. baumannii: mechanical ventilation, indwelling catheters, and admission to the ICUs [1]. In this study, the overall CRAB prevalence was higher than 90%, with IMP being a slightly more effective than MER (92.4% vs. 93.7%). This finding is similar to other reports of discordant susceptibilities to carbapenems, in which an isolate susceptible to imipenem but resistant to meropenem was reported [3, 34]. Polymyxins and TYG are the only antimicrobial options for XDR Acinetobacter. Our results revealed that COL was the most active antibiotic against A. baumannii. However, the detection of 10 COL resistant isolates in this study is worrisome. Although still uncommon, A. baumannii resistance to COL has been reported from different geographic regions [35,36,37]. Currently, for PDR A. baumannii, limited therapeutic options exist and are usually reflected in combination therapies of two or more antibiotics [38].

Among the tested CRAB isolates, blaOXA-24 was the most frequent carbapenemase gene (44.2%), followed by blaOXA-23 (34.5%), and blaNDM-1 (3.2%). Furthermore, all sequenced blaOXA-24 were identified as blaOXA-72, its single-amino-acid variant. In contrast to blaOXA-23, which is the most common acquired carbapenemase in A. baumannii worldwide [5], blaOXA-72 producing isolates have been reported in only several countries, including Croatia, Lithuania, and Brazil [39,40,41]. Results obtained in this research are in concordance with the study conducted in one pediatric hospital in Serbia, where blaOXA-24 and blaOXA-23 were also the most prevalent acquired OXAs among pediatric CRAB isolates [15]. Furthermore, blaOXA-24 was also dominant in Bulgaria (46.7%) and Croatia (97.1%), while blaOXA-23 is globally distributed, as well as in some regional countries such as Greece (96.9%) [5, 35, 39, 42]. However, contrary to our results, Novovic et al. reported blaOXA-58 in more than one-third of the tested CRAB isolated from children, indicating potential hospital dissemination of this clone [15]. Although, blaOXA-58 was also detected in all three aforementioned studies from Balkan region, its prevalence was less than 3% of CRABs [35, 39, 42]. Our results are in line with other studies showing international shift from blaOXA-58 towards blaOXA-23 or blaOXA-24 [32, 43,44,45,46].

The blaNDM-1 carrying A. baumannii has already emerged in Europe, Asia, Africa and South America [12, 44, 47, 48]. Interestingly, two reports, from France and Germany, characterized blaNDM-1 positive A. baumannii isolates obtained from patients repatriated to these countries from Serbia [16, 17]. In concordance with the above mentioned reports this study confirms that Serbia might be an endemic region for CRAB isolates carrying blaNDM-1 genes.

In the present evaluation, MLST results correlated well with PFGE clustering. The possibility that interhospital transmission of CRAB clones have occurred in Serbia is reinforced by the detection of the majority of the PFGE patterns almost uniformly distributed throughout the country. Nevertheless, with results obtained under the Pasteur MLST scheme few genetic lineages were shown to circulate in Serbia: ST636, as a singleton along with ICII representatives (ST2 and ST492), all carrying the blaOXA-66 allele of the blaOXA-51-like gene. Similar to our findings, numerous reports highlighted that ICII is widely distributed in all continents, and notably in the Mediterranean area [14, 49]. Hence, various studies indicated the worldwide distribution of the A. baumannii ST2/ICII having blaOXA-23 gene [5]. Contrastingly to the aforementioned strain, the A. baumannii ST636 harboring blaOXA-72 gene was isolated sporadically, from patients in Sweden, Lebanon, and one Russian patient from Germany [50,51,52]. Furthermore, obtained results revealed that Serbia seems to remain the reservoir for the A. baumannii pertained to ST492/ICII, carrying blaOXA-72 and blaNDM-1 genes. To the best of our knowledge, besides this study, there is only one case report of infection caused by blaOXA-72/blaNDM-1 producing A. baumannii, belonging to ICII/ST492, recovered from a urine sample of a Serbian patient hospitalized in France [16].

The limitation of the present study could be the small sample size of the randomly selected isolates for MLST and sequencing of the genes encoding carbapenemases. Nonetheless, despite these limitations, this nationwide research provides an important insight into the molecular epidemiology of the A. baumannii circulating in this region, especially comparing with the majority of the available European reports on A. baumannii which are focused on one health-care facility and particular hospital outbreak. Moreover, obtained results would serve as the base for the future studies and trend assessment of infections caused by Acinetobacter. Consequently, these data can be used to support regional initiatives to enhance infection control practices and antimicrobial stewardship, by facilitating available and inexpensive tools and resources to tackle this problem effectively and systematically.

Conclusion

In summary, this first nationwide study highlights the molecular epidemiology of the clinical isolates of A. baumannii. Alarming proportions of CRAB isolates are the consequences of the emergence of blaOXA-72, blaOXA-23, and blaNDM-1 among the tested isolates. Therefore, the extremely high antimicrobial resistance rates and the emergence of certain CRAB clones point out the critical need for the implementation of continuous surveillance of infections caused by A. baumannii and developing accurate prevention strategies in Serbia.

Availability of data and materials

All data generated or analysed during this study are included in this published article.

Abbreviations

Acb complex:

Acinetobacter calcoaceticus–baumannii complex

AK:

Amikacin

AMS:

Ampicillin-sulbactam

BMD:

Broth microdilution

CDC:

Centers for Disease Control and Prevention

CIP:

Ciprofloxacin

CLSI:

Clinical and Laboratory Standards Institute

COL:

Colistin

CAZ:

Ceftazidime

CRAB:

Carbapenem-resistant A. baumannii

EUCAST:

European Committee on Antimicrobial Susceptibility Testing

FEP:

Cefepime

GEN:

Gentamicin

ICs:

International clones

ICUs:

Intensive care units

IMP:

Imipenem

LEV:

Levofloxacin

MBLs:

Metallo-β-lactamases

MDR:

Multidrug-resistant

MER:

Meropenem

MICs:

Minimum inhibitory concentrations

MLST:

Multilocus sequence typing

PDR:

Pandrug-resistant

OXAs:

Oxacillinases

PFGE:

Pulsed-field gel electrophoresis

STs:

Sequence types

TET:

Tetracycline

TOB:

Tobramycin

TSX:

Trimethoprim-sulfamethoxazole

TYG:

Tigecycline

TZP:

Piperacillin-tazobactam

XDR:

Extensively drug-resistant

References

  1. 1.

    Kanafani ZA, Zahreddine N, Tayyar R, Sfeir J, Araj GF, Matar GM, et al. Multi-drug resistant Acinetobacter species: a seven-year experience from a tertiary care center in Lebanon. Antimicrob Resist Infect Control. 2018;7:9.

    PubMed  PubMed Central  Google Scholar 

  2. 2.

    Visca P, Seifert H, Towner KJ. Acinetobacter infection-an emerging threat to human health. IUBMB Life. 2011;63(12):1048–54.

    PubMed  CAS  Google Scholar 

  3. 3.

    Maragakis LL, Perl TM. Acinetobacter baumannii: epidemiology, antimicrobial resistance, and treatment options. Clin Infect Dis. 2008;46(8):1254–63.

    PubMed  CAS  Google Scholar 

  4. 4.

    De Rosa FG, Corcione S, Pagani N, Di Perri G. From ESKAPE to ESCAPE, from KPC to CCC. Clin Infect Dis. 2015;60(8):1289–90.

    PubMed  Google Scholar 

  5. 5.

    Mugnier PD, Poirel L, Naas T, Nordmann P. Worldwide dissemination of the blaOXA-23 carbapenemase gene of Acinetobacter baumannii. Emerg Infect Dis. 2010;16(1):35–40.

    PubMed  PubMed Central  CAS  Google Scholar 

  6. 6.

    Perez F, Hujer AM, Hujer KM, Decker BK, Rather PN, Bonomo RA. Global challenge of multidrug-resistant Acinetobacter baumannii. Antimicrob Agents Chemother. 2007;51(10):3471–84.

    PubMed  PubMed Central  CAS  Google Scholar 

  7. 7.

    Tacconelli E, Carrara E, Savoldi A, Harbath S, Mendelson M, Monnet DL, et al. Discovery, research, and development of new antibiotics: the WHO priority list of antibiotic-resistant bacteria and tuberculosis. Lancet Infect Dis. 2018;18(3):318–27.

    PubMed  Google Scholar 

  8. 8.

    Falagas ME, Bliziotis IA, Siempos II. Attributable mortality of Acinetobacter baumannii infections in critically ill patients: a systematic review of matched cohort and case-control studies. Crit Care. 2006;10(2):R48.

    PubMed  PubMed Central  Google Scholar 

  9. 9.

    Centers for Disease Control and Prevention (CDC). Antibiotic resistance threats in the United States, 2019. Atlanta: U.S. Department of Health and Human Services, CDC; 2019.

    Google Scholar 

  10. 10.

    Poirel L, Nordmann P. Carbapenem resistance in Acinetobacter baumannii: mechanisms and epidemiology. Clin Microbiol Infect. 2006;12(9):826–36.

    PubMed  CAS  Google Scholar 

  11. 11.

    Turton JF, Ward ME, Woodford N, Kaufmann ME, Pike R, Livermore DM, et al. The role of ISAba1 in expression of OXA carbapenemase genes in Acinetobacter baumannii. FEMS Microbiol Lett. 2006;258(1):72–7.

    PubMed  CAS  Google Scholar 

  12. 12.

    Bonnin RA, Poirel L, Naas T, Pirs M, Seme K, Schrenzel J, et al. Dissemination of New Delhi metallo-β-lactamase-1-producing Acinetobacter baumannii in Europe. Clin Microbiol Infect. 2012;18(9):e362–5.

    PubMed  CAS  Google Scholar 

  13. 13.

    Peleg AY, Seifert H, Paterson DL. Acinetobacter baumannii: emergence of a successful pathogen. Clin Microbiol Rev. 2008;21(3):538–82.

    PubMed  PubMed Central  CAS  Google Scholar 

  14. 14.

    Zarrilli R, Pournaras S, Giannouli M, Tsakris A. Global evolution of multidrug-resistant Acinetobacter baumannii clonal lineages. Int J Antimicrob Agents. 2013;41(1):11–9.

    PubMed  CAS  Google Scholar 

  15. 15.

    Novovic K, Mihajlovic S, Vasiljevic Z, Filipic B, Begovic J, Jovcic B. Carbapenem-resistant Acinetobacter baumannii from Serbia: revision of CarO classification. PLoS One. 2015;10(3):e0122793.

    PubMed  PubMed Central  Google Scholar 

  16. 16.

    Dortet L, Bonnin RA, Bernabeu S, Escaut L, Vittecoq D, Girlich D, et al. First occurrence of OXA-72-producing Acinetobacter baumannii in Serbia. Antimicrob Agents Chemother. 2016;60(10):5724–30.

    PubMed  PubMed Central  Google Scholar 

  17. 17.

    Pfeifer Y, Wilharm G, Zander E, Wichelhaus TA, Göttig S, Hunfeld KP, et al. Molecular characterization of blaNDM-1 in an Acinetobacter baumannii strain isolated in Germany in 2007. J Antimicrob Chemother. 2011;66(9):1998–2001.

    PubMed  CAS  Google Scholar 

  18. 18.

    Turton JF, Woodford N, Glover J, Yarde S, Kaufmann ME, Pitt TL. Identification of Acinetobacter baumannii by detection of the blaOXA-51-like carbapenemase gene intrinsic to this species. J Clin Microbiol. 2006;44(8):2974–6.

    PubMed  PubMed Central  CAS  Google Scholar 

  19. 19.

    Higgins PG, Lehmann M, Seifert H. Inclusion of OXA-143 primers in a multiplex polymerase chain reaction (PCR) for genes encoding prevalent OXA carbapenemases in Acinetobacter spp. Int J Antimicrob Agents. 2010;35(3):305.

    PubMed  CAS  Google Scholar 

  20. 20.

    Poirel L, Walsh TR, Cuvillier V, Nordmann P. Multiplex PCR for detection of acquired carbapenemase genes. Diagn Microbiol Infect Dis. 2011;70(1):119–23.

    PubMed  CAS  Google Scholar 

  21. 21.

    Woodford N, Ellington MJ, Coelho JM, Turton JF, Ward ME, Brown S, et al. Multiplex PCR for genes encoding prevalent OXA carbapenemases in Acinetobacter spp. Int J Antimicrob Agents. 2006;27(4):351–3.

    PubMed  CAS  Google Scholar 

  22. 22.

    Segal H, Garny S, Elisha BG. IS IS (ABA-1) customized for Acinetobacter? FEMS Microbiol Lett. 2005;243(2):425–9.

    PubMed  CAS  Google Scholar 

  23. 23.

    La Scola B, Gundi VA, Khamis A, Raoult D. Sequencing of the rpoB gene and flanking spacers for molecular identification of Acinetobacter species. J Clin Microbiol. 2006;44(3):827–32.

    PubMed  PubMed Central  Google Scholar 

  24. 24.

    Clinical and Laboratory Standards Institute (CLSI). Performance standards for antimicrobial susceptibility testing. In: twenty-seventh informational supplement M100-S27. Wayne: Clinical and Laboratory Standards Institute; 2017.

    Google Scholar 

  25. 25.

    European Committee on Antimicrobial Susceptibility Testing (EUCAST). Breakpoint tables for interpretation of MICs and zone diameters. Version 8.1; 2018.

    Google Scholar 

  26. 26.

    Magiorakos AP, Srinivasan A, Carey RB, Carmeli Y, Falagas ME, Giske CG, et al. Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance. Clin Microbiol Infect. 2012;18(3):268–81.

    PubMed  CAS  Google Scholar 

  27. 27.

    Yong D, Lee K, Yum JH, Shin HB, Rossolini GM, Chong Y. Imipenem-EDTA disk method for differentiation of metallo-beta-lactamase-producing clinical isolates of Pseudomonas spp. and Acinetobacter spp. J Clin Microbiol. 2002;40(10):3798–801.

    PubMed  PubMed Central  CAS  Google Scholar 

  28. 28.

    Kojic M, Strahinic I, Topisirovic L. Proteinase PI and lactococcin a genes are located on the largest plasmid in Lactococcus lactis subsp. lactis bv. diacetylactis S50. Can J Microbiol. 2005;51(4):305–14.

    PubMed  CAS  Google Scholar 

  29. 29.

    Diancourt L, Passet V, Nemec A, Dijkshoorn L, Brisse S. The population structure of Acinetobacter baumannii: expanding multiresistant clones from an ancestral susceptible genetic pool. PLoS One. 2010;5(4):e10034.

    PubMed  PubMed Central  Google Scholar 

  30. 30.

    Banerjee T, Mishra A, Das A, Sharma S, Barman H, Yadav G. High prevalence and Endemicity of multidrug resistant Acinetobacter spp. in intensive care unit of a tertiary care hospital, Varanasi, India. J Pathog. 2018;2018:9129083.

    PubMed  PubMed Central  Google Scholar 

  31. 31.

    El Kettani A, Maaloum F, Diawara I, Katfy K, Harrar N, Zerouali K, et al. Prevalence of Acinetobacter baumannii bacteremia in intensive care units of Ibn Rochd University hospital, Casablanca. Iran J Microbiol. 2017;9(6):318–23.

    PubMed  PubMed Central  Google Scholar 

  32. 32.

    Rosales-Reyes R, Gayosso-Vázquez C, Fernández-Vázquez JL, Jarillo-Quijada MD, Rivera-Benítez C, Santos-Preciado JI, et al. Virulence profiles and innate immune responses against highly lethal, multidrug-resistant nosocomial isolates of Acinetobacter baumannii from a tertiary care hospital in Mexico. PLoS One. 2017;12(8):e0182899.

    PubMed  PubMed Central  Google Scholar 

  33. 33.

    Wang D, Ma L, Wu Z, Li M, Li X, Zhang W, et al. Identification and characteristics of imipenem-resistant Acinetobacter baumannii in surgical wards in a Chinese university hospital. Infect Dis (London, England). 2015;47(3):182–6.

    CAS  Google Scholar 

  34. 34.

    Jones RN, Sader HS, Fritsche TR, Rhomberg PR. Carbapenem susceptibility discords among Acinetobacter isolates. Clin Infect Dis. 2006;42(1):158.

    PubMed  Google Scholar 

  35. 35.

    Pournaras S, Dafopoulou K, Del Franco M, Zarkotou O, Dimitroulia E, Protonotariou E, et al. Predominance of international clone 2 OXA-23-producing-Acinetobacter baumannii clinical isolates in Greece, 2015: results of a nationwide study. Int J Antimicrob Agents. 2017;49(6):749–53.

    PubMed  CAS  Google Scholar 

  36. 36.

    Qureshi ZA, Hittle LE, O'Hara JA, Rivera JI, Syed A, Shields RK, et al. Colistin-resistant Acinetobacter baumannii: beyond carbapenem resistance. Clin Infect Dis. 2015;60(9):1295–303.

    PubMed  PubMed Central  Google Scholar 

  37. 37.

    Snyman Y, Whitelaw AC, Reuter S, Dramowski A, Maloba MRB, Newton-Foot M. Clonal expansion of colistin-resistant Acinetobacter baumannii isolates in Cape Town, South Africa. Int J Infect Dis. 2020;91:94–100.

    PubMed  CAS  Google Scholar 

  38. 38.

    Leite GC, Oliveira MS, Perdigão-Neto LV, Rocha CK, Guimarães T, Rizek C, et al. Antimicrobial combinations against pan-resistant Acinetobacter baumannii isolates with different resistance mechanisms. PLoS One. 2016;11(3):e0151270.

    PubMed  PubMed Central  Google Scholar 

  39. 39.

    Franolić-Kukina I, Bedenić B, Budimir A, Herljević Z, Vraneš J, Higgins PG. Clonal spread of carbapenem-resistant OXA-72-positive Acinetobacter baumannii in a Croatian university hospital. Int J Infect Dis. 2011;15(10):e706–9.

    PubMed  Google Scholar 

  40. 40.

    Povilonis J, Seputiene V, Krasauskas R, Juskaite R, Miskinyte M, Suziedelis K, et al. Spread of carbapenem-resistant Acinetobacter baumannii carrying a plasmid with two genes encoding OXA-72 carbapenemase in Lithuanian hospitals. J Antimicrob Chemother. 2013;68(5):1000–6.

    PubMed  CAS  Google Scholar 

  41. 41.

    Vasconcelos AT, Barth AL, Zavascki AP, Gales AC, Levin AS, Lucarevschi BR, et al. The changing epidemiology of Acinetobacter spp. producing OXA carbapenemases causing bloodstream infections in Brazil: a BrasNet report. Diagn Microbiol Infect Dis. 2015;83(4):382–5.

    PubMed  CAS  Google Scholar 

  42. 42.

    Strateva T, Sirakov I, Stoeva T, Stratev A, Dimov S, Savov E, et al. Carbapenem-resistant Acinetobacter baumannii: current status of the problem in four Bulgarian university hospitals (2014-2016). J Glob Antimicrob Resist. 2019;16:266–73.

    PubMed  Google Scholar 

  43. 43.

    Adams-Haduch JM, Onuoha EO, Bogdanovich T, Tian GB, Marschall J, Urban CM, et al. Molecular epidemiology of carbapenem-nonsusceptible Acinetobacter baumannii in the United States. J Clin Microbiol. 2011;49(11):3849–54.

    PubMed  PubMed Central  CAS  Google Scholar 

  44. 44.

    Djahmi N, Dunyach-Remy C, Pantel A, Dekhil M, Sotto A, Lavigne JP. Epidemiology of carbapenemase-producing Enterobacteriaceae and Acinetobacter baumannii in Mediterranean countries. Biomed Res Int. 2014;2014:305784.

    PubMed  PubMed Central  Google Scholar 

  45. 45.

    Schleicher X, Higgins PG, Wisplinghoff H, Körber-Irrgang B, Kresken M, Seifert H. Molecular epidemiology of Acinetobacter baumannii and Acinetobacter nosocomialis in Germany over a 5-year period (2005-2009). Clin Microbiol Infect. 2013;19(8):737–42.

    PubMed  CAS  Google Scholar 

  46. 46.

    Wang TH, Leu YS, Wang NY, Liu CP, Yan TR. Prevalence of different carbapenemase genes among carbapenem-resistant Acinetobacter baumannii blood isolates in Taiwan. Antimicrob Resist Infect Control. 2018;7:123.

    PubMed  PubMed Central  Google Scholar 

  47. 47.

    Chen Y, Zhou Z, Jiang Y, Yu Y. Emergence of NDM-1-producing Acinetobacter baumannii in China. J Antimicrob Chemother. 2011;66(6):1255–9.

    PubMed  CAS  Google Scholar 

  48. 48.

    Villacís JE, Bovera M, Romero-Alvarez D, Cornejo F, Albán V, Trueba G, et al. NDM-1 carbapenemase in Acinetobacter baumannii sequence type 32 in Ecuador. New Microbes New Infect. 2019;29:100526.

    PubMed  PubMed Central  Google Scholar 

  49. 49.

    Karah N, Sundsfjord A, Towner K, Samuelsen Ø. Insights into the global molecular epidemiology of carbapenem non-susceptible clones of Acinetobacter baumannii. Drug Resist Updat. 2012;15(4):237–47.

    PubMed  CAS  Google Scholar 

  50. 50.

    Al Atrouni A, Hamze M, Jisr T, Lemarié C, Eveillard M, Joly-Guillou ML, et al. Wide spread of OXA-23-producing carbapenem-resistant Acinetobacter baumannii belonging to clonal complex II in different hospitals in Lebanon. Int J Infect Dis. 2016;52:29–36.

    PubMed  Google Scholar 

  51. 51.

    Eigenbrod T, Reuter S, Gross A, Kocer K, Günther F, Zimmermann S, et al. Molecular characterization of carbapenem-resistant Acinetobacter baumannii using WGS revealed missed transmission events in Germany from 2012-15. J Antimicrob Chemother. 2019;74(12):3473–80.

    PubMed  Google Scholar 

  52. 52.

    Karah N, Dwibedi CK, Sjöström K, Edquist P, Johansson A, Wai SN, et al. Novel aminoglycoside resistance transposons and transposon-derived circular forms detected in Carbapenem-resistant Acinetobacter baumannii clinical isolates. Antimicrob Agents Chemother. 2016;60(3):1801–18.

    PubMed  PubMed Central  CAS  Google Scholar 

Download references

Acknowledgments

We gratefully acknowledge the following persons for supplying the strains used in this study: Anita Sente Zigmanovic, Desanka Mojasevic, Ljiljana Radosavljevic, Snezana Delic, Mirjana Hadnadjev, Branislava Kocic, Dragana Andjelkovic and Lidija Boskovic.

Funding

This work was supported by the Ministry of Education, Science and Technological Development of the Republic of Serbia [Grant Nos. 175039] and the Science Fund of the Republic of Serbia [IN-DEPTH].

Author information

Author notes

  1. Bojana Lukovic and Ina Gajic contributed equally to this work.

Affiliations

  1. Institute of Microbiology and Immunology, Medical Faculty, University of Belgrade, Doktora Subotica starijeg 1, Belgrade, 11000, Serbia

    Bojana Lukovic, Ina Gajic, Dusan Kekic, Nataša Opavski & Lazar Ranin

  2. Faculty of Biology, University of Belgrade, Belgrade, Serbia

    Ivica Dimkic

  3. Department of Microbiology, Clinical Center Kragujevac, Kragujevac, Serbia

    Sanja Zornic

  4. Department of Microbiology, General Hospital Subotica, Subotica, Serbia

    Tatjana Pozder

  5. Department of Microbiology, General Hospital Pancevo, Pancevo, Serbia

    Svetlana Radisavljevic

  6. Laboratory for Molecular Microbiology, Institute of Molecular Genetics and Genetic Engineering, University of Belgrade, Belgrade, Serbia

    Milan Kojic

Authors
  1. Bojana Lukovic
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Ina Gajic
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Ivica Dimkic
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Dusan Kekic
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Sanja Zornic
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Tatjana Pozder
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Svetlana Radisavljevic
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Nataša Opavski
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Milan Kojic
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Lazar Ranin
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

BL, IG, and LR participated in the protocol development, study design and study management. BL and IG participated in data interpretation and writing the manuscript. BL, IG, NO, LR, SZ, TP and SR provided the bacterial strains. BL, IG, SZ, TP and SR participated in the identification of strains and performing the antimicrobial susceptibility tests. BL and IG performed PCRs and assessed the mechanisms of resistance. BL, IG and ID participated in the MLST including the analysis of gene sequences. DK and MK performed the PFGE. NO, ID and MK critically reviewed the manuscript. All authors read and approved the final manuscript.

Corresponding authors

Correspondence to Bojana Lukovic or Ina Gajic.

Ethics declarations

Ethics approval and consent to participate

The study was approved by the ethical committee of the Medical Faculty, University of Belgrade (1550/II-4).

Consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Lukovic, B., Gajic, I., Dimkic, I. et al. The first nationwide multicenter study of Acinetobacter baumannii recovered in Serbia: emergence of OXA-72, OXA-23 and NDM-1-producing isolates. Antimicrob Resist Infect Control 9, 101 (2020). https://doi.org/10.1186/s13756-020-00769-8

Download citation

Keywords

  • Acinetobacter baumannii
  • CRAB
  • bla OXA23
  • bla OXA72
  • bla NDM-1
  • ST492
  • ST636

Antimicrobial Resistance & Infection Control

ISSN: 2047-2994

Contact us